|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvedBy
|
2003
|
|
gptkbp:ATCCode
|
J05AE08
|
|
gptkbp:bioavailability
|
60% (oral)
|
|
gptkbp:CASNumber
|
gptkb:163706-06-7
|
|
gptkbp:contraindication
|
severe hepatic impairment
concurrent use with certain drugs (e.g., rifampin)
|
|
gptkbp:eliminationHalfLife
|
6-7 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
XJXATXFEYFJXQX-GXFFZTMASA-N
|
|
gptkbp:hasMolecularFormula
|
C38H52N6O7
|
|
gptkbp:hasSMILES
|
CC(C)[C@@H](C(=O)N1CCCC1(Cc2ccccc2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N(C)C)NC(=O)OC(C)(C)C
|
|
gptkbp:hasUNII
|
83T1F4QUIM
|
|
gptkbp:IUPACName
|
N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-2-[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]pyrrolidine-2-carboxamide
|
|
gptkbp:legalStatus
|
prescription only
patent expired in US (2022)
|
|
gptkbp:listedOn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:marketedAs
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:mechanismOfAction
|
HIV-1 protease inhibitor
|
|
gptkbp:meltingPoint
|
205-207°C
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:molecularWeight
|
704.9 g/mol
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
148192
CHEMBL933
DB01072
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
headache
jaundice
rash
hyperbilirubinemia
|
|
gptkbp:synonym
|
gptkb:Atazanavir
|
|
gptkbp:usedFor
|
gptkb:antiviral_drug
HIV infection
|
|
gptkbp:bfsParent
|
gptkb:AR-C
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
163706-06-7
|